Sentinel Oncology

What Sentinel Oncology does

Sentinel Oncology Limited is a privately-held, Cambridge UK-based drug discovery company founded in 2005 that develops small-molecule therapeutics for oncology and CNS disorders, with particular focus on agents capable of crossing the blood-brain barrier to treat primary brain tumours and metastatic brain disease. The company's pipeline centres on three differentiated mechanisms: SOL578, a checkpoint kinase 1 (Chk1) inhibitor out-licensed to PharmaEngine; SOL686, an allosteric Polo-like kinase 1 (Plk1) inhibitor targeting the Polo-box domain; and SOL784 (FS115), a brain-penetrant S6K1 inhibitor for Fragile X syndrome. Additional preclinical work targets hypoxia-activated DNA-repair pathway disruptors for glioblastoma. The science traces back to collaborations with Prof. Ashok Venkitaraman (University of Cambridge/MRC Cancer Unit) and Prof. Anthony Chalmers (Glasgow), and the company has secured over 60 patents through CEO Robert Boyle and the medicinal chemistry team.

Sentinel operates on a capital-efficient, asset-out-licensing business model rather than independent clinical development. Revenue derives from a combination of non-dilutive grant funding (Wellcome Trust Seeding Drug Discovery, Innovate UK, MRC Biomedical Catalyst, Eurostars, EEDA totalling several million GBP over 2005-2018) and licensing transactions — including a 2014 Chk1 deal with Oncothyreon (up to $174M in milestones) and a 2022 exclusive worldwide licence with PharmaEngine for SOL578 ($140.5M in development, regulatory and sales milestones plus tiered royalties). PharmaEngine dosed the first patient in a Phase 1 haematological cancer trial in August 2023. Additional partnerships with McQuade Center/Otsuka (SOL784), PhoreMost (SOL686), Horizon Discovery and several UK universities support outsourcing-led drug discovery. The company runs a small full-time team (1-10 employees) supplemented by an extended scientific advisory board, and explicitly seeks partnering or licensing exits at the candidate-drug or IND stage rather than building an internal commercial sales infrastructure.

Name

Sentinel Oncology

Legal name

Sentinel Oncology Limited

Website

https://sentineloncology.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

1–10 employees

Short description

Sentinel Oncology is a Cambridge UK-based small-molecule drug discovery company founded in 2005 that designs selective oncology and CNS candidates — including brain-penetrant Chk1, allosteric PLK1, and S6K1 inhibitors — and monetizes them through licensing deals with pharmaceutical partners rather than internal commercialization.

Ownership category

akta.pro rank

Product category

Oncology Drug Discovery

NAICS

Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Oncology drug discovery
• Small molecule therapeutics
• Brain cancer research
• DNA damage response
• Preclinical drug development

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Licensing and Milestone Payments: Exclusive worldwide license agreements with upfront payments, development and regulatory milestones, and sales milestones plus royalties from net product sales. Example: PharmaEngine deal valued at $140.5 million plus royalties.
2. Collaborative R&D Partnerships: Co-development agreements where partners fund IND-enabling studies and provide milestone payments. Sentinel provides drug discovery expertise while partners provide funding and development capabilities.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels4 records

Core offering

Sentinel Oncology is a drug discovery company developing small molecule drug candidates for oncology and central nervous system (CNS) disorders. The company designs, optimises, and advances candidate drugs targeting DNA damage response pathways, mitotic processes, and protein kinases implicated in cancer and neurological diseases, with particular focus on brain-penetrant therapies for primary and metastatic brain tumours. Its primary commercial activity is out-licensing these pre-clinical and early-clinical-stage drug candidates to pharmaceutical and biotechnology partners for further development and commercialisation.

Product overview

Sentinel Oncology is a fully integrated drug discovery company developing a portfolio of small molecule drug candidates for oncology and rare diseases. The company operates with a partnering business model, seeking licensing and collaborative opportunities for programmes at candidate drug or IND phase. The core pipeline includes three named candidates: SOL578 (Chk1 inhibitor for hematological and brain cancers, licensed to PharmaEngine), SOL686 (allosteric Plk1 inhibitor for glioma, with option granted to undisclosed partner), and SOL784 (S6K1 inhibitor for fragile X syndrome, in collaboration with McQuade Center/Otsuka). Additional pre-candidate drug programmes focus on brain cancers including glioblastoma.

Differentiator

Problem solved

Functional benefit

Products and services

• SOL578 SOL578 is a small molecule checkpoint kinase 1 (Chk1) inhibitor with high kinase selectivity and oral bioavailability, targeting the DNA damage response (DDR) network for the treatment of haematological cancers (including AML and MCL) and brain cancers. It has demonstrated preclinical activity as monotherapy and in combination with chemotherapy agents. Out-licensed exclusively worldwide to PharmaEngine, Inc.
• SOL686 SOL686 is a novel allosteric Polo-like kinase 1 (Plk1) inhibitor that targets the Polo-box domain (PBD) rather than the kinase active site, aiming to mitigate the adverse events seen with conventional active-site Plk1 inhibitors. The compound demonstrates excellent brain exposure and outstanding tumour control in orthotopic brain cancer models, and is being developed for glioma. It was in-licensed from PhoreMost Ltd in 2017.
• SOL784 SOL784 is a brain-penetrant small molecule S6K1 inhibitor being developed to address the underlying disease biology of Fragile X syndrome (FXS), a genetic neurodevelopmental disorder and the single largest cause of genetically inherited intellectual disability. Lead compound FS115 is an oral brain-penetrant inhibitor that has shown robust efficacy in FXS and triple-negative breast cancer models. Clinical development is supported through a collaboration with the McQuade Center (MSRD, member of the Otsuka family).

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered flagship, minor, core and historical.

• PharmaEngine, Inc.flagshipOEM/ Whitelabel/ Licensing Partner · 26 September 2022Exclusive worldwide license agreement for SOL578 (Chk1 inhibitor) development and commercialization. Sentinel eligible to receive $140.5M from development, regulatory and sales milestones plus royalties from net product sales. PharmaEngine initiated Phase 1 trial in August 2023.
• FRAXA Research FoundationminorGTM or Marketing Partner · 8 July 2022Co-hosted 'Fragile X Syndrome: Innovative Approaches to Finding a Cure' event with WuXi AppTec on Fragile X Syndrome Awareness Day. David Walker presented Sentinel's differentiated approach to FXS treatment.
• WuXi AppTecminorGTM or Marketing Partner · 8 July 2022Co-hosted Fragile X Syndrome awareness event to advance breakthroughs for rare disease patients and raise public awareness.
• McQuade Center for Strategic Research and Development (MSRD)coreStrategic or Co-development Partner · 2 September 2021Agreement with MSRD (member of Otsuka family) to support clinical development of SOL784 for Fragile X syndrome. Addresses underlying disease biology of this rare genetic condition.
• PharmaEngine, Inc.coreStrategic or Co-development Partner · 26 November 2020Initial collaboration and license option agreement for SOL-578. PharmaEngine funded IND-enabling studies and obtained option for exclusive worldwide rights. Sentinel received exclusivity payment and eligible for milestone payments and tiered royalties.
• PhoreMost LimitedcoreStrategic or Co-development Partner · 4 November 2019Extended collaboration to accelerate SOL686 allosteric PLK1 inhibitor development for glioma treatment. Both companies received Innovate UK funding. Programme originated from Prof Venkitaraman's laboratory at Cambridge.
• NMI TT PharmaservicesminorStrategic or Co-development Partner · 2 May 2016Eurostars grant consortium (FXSFIX) for companion diagnostic biomarker development to complement SOL101/SOL784 development for Fragile X Syndrome. NMI used DigiWest protein profiling technology.
• Oncothyreon Inc.historicalStrategic or Co-development Partner · 22 April 2014Collaboration for development of Sentinel's Chk1 programme. Oncothyreon funded additional drug discovery research and received exclusive license. Sentinel eligible for milestone payments up to $174M and royalties.
• Horizon DiscoveryhistoricalStrategic or Co-development Partner · 22 April 2013Collaboration to develop small molecule inhibitors of novel oncology target HD-001. Sentinel contributed medicinal chemistry services; programme partnered with top 10 pharma company. Sentinel entitled to milestone payments and royalties.
• Professor Anthony Chalmers / University of GlasgowcoreStrategic or Co-development Partner · 1 March 2013Discovery collaboration with Prof Chalmers (MRC Senior Clinical Fellowship, Chair of Clinical Oncology) for treatment of CNS tumours. Prof Chalmers joined Sentinel's Scientific Advisory Board. MRC Industrial Partnership Award funded proof of concept studies.
• Professor Ashok Venkitaraman / University of CambridgecoreStrategic or Co-development PartnerCo-founder and non-executive director; chairs Sentinel's Scientific Advisory Board. Distinguished Professor at Cambridge MRC Cancer Unit. Work on hypoxia-activated drugs and PLK1 inhibitors originated from his laboratory. Joint research on exploiting tumour hypoxia and DNA repair pathways.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Astex Therapeutics: Cambridge-based small molecule drug discovery company that has historically partnered with large pharma and specialised in fragment-based oncology discovery. Highly comparable virtual/semi-virtual discovery model and oncology focus, with multiple Sentinel team members (Boyle, Travers, Walker) having worked at Astex.
• PhoreMost: Cambridge-based drug discovery company focused on targeted protein degradation and allosteric targeting using its SITESEEKER platform. Existing collaboration partner on Sentinel's SOL686 allosteric PLK1 programme; comparable size, location, and oncology focus.
• Mission Therapeutics: Cambridge-based small molecule drug discovery company developing deubiquitinase inhibitors for cancer and other diseases. Similar headcount range, virtual discovery model, oncology focus, and grant/partner funding profile.
• Storm Therapeutics: Cambridge-based biotech developing small molecule inhibitors of RNA-modifying enzymes for oncology. Comparable size, oncology focus, and Cambridge Science Park adjacency; has attracted similar Wellcome/Innovate UK grant support.
• Bicycle Therapeutics: Cambridge UK-based biotech developing bicycle-based therapeutics for cancer and other diseases. Highly comparable Cambridge location, oncology focus, and partnering-driven business model, though with a more advanced pipeline and public listing.

Emerging players

• Carrick Therapeutics: Ireland/UK-based oncology drug discovery and development company focused on precision medicines for cancer. Comparable stage and partnering-driven model, with similar small-molecule oncology programmes.
• Ellipses Pharma: UK-based oncology drug development company focused on acquiring and developing clinical-stage cancer therapies. Similar emphasis on cancer indications and partnership-driven model, though Ellipses focuses on clinical-stage assets rather than discovery.
• Monte Rosa Therapeutics: Boston/Cambridge-area biotech developing small molecule degraders (molecular glues) for cancer and other diseases. Comparable preclinical/early clinical oncology focus and small-molecule platform, though at a later stage of development and financing.

Broad incumbents

• AstraZeneca: Global biopharmaceutical company headquartered near Cambridge with deep expertise in oncology drug development and historical connections to Sentinel's leadership (multiple Sentinel team members came from Astra/AstraZeneca). Relevant as both a potential acquirer/partner and a benchmark for commercial oncology development.

Others

• Domainex: UK-based drug discovery CRO with medicinal chemistry and biology services. Comparable Cambridge-area footprint and one of Sentinel's recent hires (Dr Meriel Major) came from Domainex; relevant as both a service provider and as a model of how UK CRO/discovery businesses operate in the same ecosystem.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sentinel-oncology-limited

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds15 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sentinel Oncology